Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 12, 2013, Pages 1136-1142

  Bunzeck, Nico ^a   Singh Curry, Victoria ^b,c   Eckart, Cindy ^a   Weiskopf, Nikolaus ^c   Perry, Richard J ^d   Bain, Peter G ^d   Düzel, Emrah ^b,e,f   Husain, Masud ^b,c,g,h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Basal ganglia; Iron; Magnetic resonance imaging; Motor subtypes; Parkinson's disease

Indexed keywords

IRON;

AGED; AKINETIC RIGID SYMPTOM; ARTICLE; BASAL GANGLION; BRAIN LEVEL; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOBUS PALLIDUS; HUMAN; IRON BRAIN LEVEL; IRON LOADING; IRON METABOLISM; MAGNETIZATION TRANSFER; MALE; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PUTAMEN; RADIOLOGICAL PARAMETERS; SUBSTANTIA NIGRA; THALAMUS; TRANSVERSE RELAXATION RATE; TREMOR DOMINANT SYMPTOM;

BASAL GANGLIA; IRON; MAGNETIC RESONANCE IMAGING; MOTOR SUBTYPES; PARKINSON'S DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BASAL GANGLIA; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSON DISEASE; PHENOTYPE; TREMOR;

EID: 84889095684     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.08.011     Document Type: Article

References (32)

1. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010, 16:653-661.
2. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. JNeuropathol Exp Neurol 1991, 50:743-755.
3. Rajput A.H., Sitte H.H., Rajput A., Fenton M.E., Pifl C., Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008, 70:1403-1410.
4. Selikhova M., Williams D.R., Kempster P.A., Holton J.L., Revesz T., Lees A.J. Aclinico-pathological study of subtypes in Parkinson's disease. Brain 2009, 132:2947-2957.
5. Antonini A., Vontobel P., Psylla M., Gunther I., Maguire P.R., Missimer J., et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995, 52:1183-1190.
6. Sian-Hülsmann J., Mandel S., Youdim M.B.H., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. JNeurochem 2011, 118:939-957.
7. Oberhauser E., Weinstein V., Asenjo A. Iron concentration bal ganglia and cerebral cortex obtained by overloading rabbits and monkeys with iron dextran. JNeurosurg 1970, 32:677-679.
8. Draganski B., Ashburner J., Hutton C., Kherif F., Frackowiak R.S.J., Helms G., et al. Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ). Neuroimage 2011, 55:1423-1434.
9. Péran P., Cherubini A., Assogna F., Piras F., Quattrocchi C., Peppe A., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133:3423-3433.
10. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
11. Wolff S.D., Balaban R.S. Magnetization transfer contrast (MTC) and tissue water proton relaxation invivo. Magn Reson Med 1989, 10:135-144.
12. Eckert T., Sailer M., Kaufmann J., Schrader C., Peschel T., Bodammer N., et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004, 21:229-235.
13. Bunzeck N., Schütze H., Stallforth S., Kaufmann J., Düzel S., Heinze H.-J., et al. Mesolimbic novelty processing in older adults. Cereb Cortex 2007, 17:2940-2948.
14. Fasano M., Bergamasco B., Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. JNeurochem 2006, 96:909-916.
15. Helms G., Draganski B., Frackowiak R., Ashburner J., Weiskopf N. Improved segmentation of deep brain grey matter structures using magnetization transfer (MT) parameter maps. Neuroimage 2009, 47:194-198.
16. Han X., Jovicich J., Salat D., van der Kouwe A., Quinn B., Czanner S., et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006, 32:180-194.
17. Leach L.F., Henson R.K. The use and impact of adjusted R2 effects in published regression research. Mult Linear Regres Viewp 2007, 33:1-11.
18. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46.
19. Hughes A.J., Daniel S.E., Blankson S., Lees A.J. Aclinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993, 50:140-148.
20. Kang G.A., Bronstein J.M., Masterman D.L., Redelings M., Crum J.A., Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005, 20:1133-1142.
21. Christenson G.A., Faber R.J., de Zwaan M., Raymond N.C., Specker S.M., Ekern M.D., et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. JClin Psychiatry 1994, 55:5-11.
22. Jankovic J., Kapadia A.S. Functional decline in Parkinson disease. Arch Neurol 2001, 58:1611-1615.
23. Sung Y.H., Chung S.J., Kim S.R., Lee M.C. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease. Mov Disord 2008, 23:137-140.
24. Evans A.H., Katzenschlager R., Paviour D., O'Sullivan J.D., Appel S., Lawrence A.D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004, 19:397-405.
25. Seppi K., Schocke M.F. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 2005, 18:370-375.
26. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. JNeurochem 1995, 65:710-724.
27. Friedman A., Galazka-Friedman J., Koziorowski D. Iron as a cause of Parkinson disease - a myth or a well established hypothesis?. Parkinsonism Relat Disord 2009, 15(Suppl.3):S212-S214.
28. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010, 92:330-344.
29. Lv Z., Jiang H., Xu H., Song N., Xie J. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. JNeural Transm 2011, 118:361-369.
30. Gotz M.E., Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004, 1012:193-208.
31. Burn D.J., Rowan E.N., Allan L.M., Molloy S., O'Brien J.T., McKeith I.G. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. JNeurol Neurosurg Psychiatry 2006, 77:585-589.
32. Alves G., Larsen J.P., Emre M., Wentzel-Larsen T., Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006, 21:1123-1130.